Comparative Pharmacology
Head-to-head clinical analysis: HETRAZAN versus VANSIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETRAZAN versus VANSIL.
HETRAZAN vs VANSIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Category C
Category C
Anthelmintic
Anthelmintic